Syndax at H.C. Wainwright conference: recurring revenue takes center stage

On Tuesday, September 15th, 2026, Syndax Pharmaceuticals (SNDX) addressed the H.C. Wainwright 28th Annual Global Investment Conference to discuss a business model increasingly driven by recurring revenue. The company's two marketed drugs, Revuforj and Niktimvo, are both in their second year of commercialization and have already generated annual revenue exceeding $200 million.

Revuforj, specifically, is experiencing a shift in its revenue mix toward post-transplant maintenance use, which the management identifies as a key long-term growth driver. Roughly 80% of Revuforj patients are now co-treated with standard-of-care therapy, and up to 70% of transplant patients receive Revuforj as maintenance therapy.

Near-term catalysts include upcoming data from axatilimab studies in idiopathic pulmonary fibrosis and frontline cGVHD. Syndax expects to have four potentially differentiated pipeline assets and two approved medicines in clinical trials by 2027. Currently, the company is operating at peak capacity for a small biopharmaceutical firm, with both commercial assets contributing to growth.

The revenue mix is steadily transitioning, with Syndax reporting that a growing portion of revenue is tied to repeat use, rather than solely new prescriptions. CFO Keith Goldhan highlighted that the longer-term growth story hinges on the recurring revenue generated by Revuforj, having now become the dominant revenue source in recent periods.

Real-world evidence demonstrates that the majority of Revuforj patients are receiving the drug in combination with standard therapy, and a significant number progress to stem cell transplantation, subsequently receiving Revuforj as post-transplant maintenance.